Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 21, 2016, Pages E2973-E2982

  Gross, Catharina C ^a   Schulte Mecklenbeck, Andreas ^a   Rünzi, Anna ^a   Kuhlmann, Tanja ^a   Posevitz Fejfár, Anita ^a   Schwab, Nicholas ^a   Schneider Hohendorf, Tilman ^a   Herich, Sebastian ^a   Held, Kathrin ^b   Konjević, Matea ^b   Hartwig, Marvin ^a   Dornmair, Klaus ^b,c   Hohlfeld, Reinhard ^b,c   Ziemssen, Tjalf ^d   Klotz, Luisa ^a   Meuth, Sven G ^a,e   Wiendl, Heinz ^a,e  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Technische Universität München Munich Cluster for Systems Neurology   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Daclizumab; DNAM 1; Il 2 receptor; Multiple sclerosis; Nk cells

Indexed keywords

ALPHA4 INTEGRIN; ANTIGEN; BETA INTERFERON; BETA1 INTEGRIN; CD146 ANTIGEN; CD155 ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; DNAX ACCESSORY MOLECULE 1; GRANZYME; GRANZYME K; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; L SELECTIN; MYELIN BASIC PROTEIN; NATALIZUMAB; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; CD226 ANTIGEN; POLIOVIRUS RECEPTOR; T LYMPHOCYTE ANTIGEN; VIRUS RECEPTOR;

ARTICLE; BLOOD ANALYSIS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL MIGRATION; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CYTOLYSIS; DEMYELINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREGULATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; BLOOD BRAIN BARRIER; CELL MOTION; DRUG EFFECTS; FEMALE; IMMUNOLOGY; K-562 CELL LINE; LYMPHOCYTE ACTIVATION; MALE; PATHOLOGY;

ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BLOOD-BRAIN BARRIER; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; FEMALE; HUMANS; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MULTIPLE SCLEROSIS; NATALIZUMAB; RECEPTORS, INTERLEUKIN-2; RECEPTORS, VIRUS;

EID: 84969800138     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1524924113     Document Type: Article

References (74)

1. Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15(9):545-558.
2. Kingwell E, et al. (2013) Incidence and prevalence of multiple sclerosis in Europe: A systematic review. BMC Neurol 13(128):128.
3. Sawcer S, et al.; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2 (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476(7359): 214-219.
4. Wiendl H, Gross CC (2013) Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol 9(7):394-404.
5. Cerboni C, et al. (2007) Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood 110(2):606-615.
6. Ardolino M, et al. (2011) DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: Relevance for NK-T cell interaction. Blood 117(18):4778-4786.
7. Farag SS, Caligiuri MA (2006) Human natural killer cell development and biology. Blood Rev 20(3):123-137.
8. Molinero LL, Fuertes MB, Rabinovich GA, Fainboim L, Zwirner NW (2002) Activationinduced expression of MICA on T lymphocytes involves engagement of CD3 and CD28. J Leukoc Biol 71(5):791-797.
9. Maasho K, Opoku-Anane J, Marusina AI, Coligan JE, Borrego F (2005) NKG2D is a costimulatory receptor for human naive CD8+ T cells. J Immunol 174(8):4480-4484.
10. Bielekova B, et al. (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103(15):5941-5946.
11. Cerboni C, Ardolino M, Santoni A, Zingoni A (2009) Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: Role of NKG2D ligands released by activated T cells. Blood 113(13):2955-2964.
12. Cella M, et al.; CHAVI Clinical Core B; NIAID Center for HIV/AIDS Vaccine Immunology (2010) Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection. Eur J Immunol 40(4):949-954.
13. Lanier LL (2008) Up on the tightrope: Natural killer cell activation and inhibition. Nat Immunol 9(5):495-502.
14. Andresen L, Jensen H, Pedersen MT, Hansen KA, Skov S (2007) Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells. J Immunol 179(12):8235-8242.
15. Matusali G, Potestà M, Santoni A, Cerboni C, Doria M (2012) The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cellactivating ligand PVR. J Virol 86(8):4496-4504.
16. Hafler JP, et al.; International Multiple Sclerosis Genetics Consortium (IMSGC) (2009) CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun 10(1): 5-10.
17. Alcina A, et al. (2010) The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. Genes Immun 11(5):439-445.
18. Qiu ZX, Zhang K, Qiu XS, Zhou M, Li WM (2013) CD226 Gly307Ser association with multiple autoimmune diseases: A meta-analysis. Hum Immunol 74(2):249-255.
19. Nielsen N, ∅dum N, Ursø B, Lanier LL, Spee P (2012) Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PLoS One 7(2):e31959.
20. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22(11):633-640.
21. Cooper MA, et al. (2001) Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 97(10):3146-3151.
22. Perini P, et al. (2000) Effect of IFNbeta and anti-IFNbeta antibodies on NK cells in multiple sclerosis patients. J Neuroimmunol 105(1):91-95.
23. Saraste M, Irjala H, Airas L (2007) Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 28(3):121-126.
24. Vandenbark AA, et al. (2009) Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 215(1-2):125-128.
25. Sand KL, Knudsen E, Rolin J, Al-Falahi Y, Maghazachi AA (2009) Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol Life Sci 66(8):1446-1456.
26. Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E (2010) Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol 63(5):311-317.
27. Skarica M, Eckstein C, Whartenby KA, Calabresi PA (2011) Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol 235(1-2):70-76.
28. Johnson TA, et al. (2011) Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients. J Immunol 187(1): 570-579.
29. Kowarik MC, et al. (2011) Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 76(14):1214-1221.
30. Martin JF, Perry JS, Jakhete NR, Wang X, Bielekova B (2010) An IL-2 paradox: Blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol 185(2):1311-1320.
31. Jiang W, Chai NR, Maric D, Bielekova B (2011) Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol 187(2):781-790.
32. Kappos L, et al. (2015) Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 373(15):1418-1428.
33. Bielekova B, et al. (2009) Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 66(4):483-489.
34. Bielekova B, et al. (2011) Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 77(21):1877-1886.
35. Wynn D, et al.; CHOICE investigators (2010) Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 9(4):381-390.
36. Caligiuri MA (2008) Human natural killer cells. Blood 112(3):461-469.
37. Man S, Ubogu EE, Ransohoff RM (2007) Inflammatory cell migration into the central nervous system: A few new twists on an old tale. Brain Pathol 17(2):243-250.
38. Schneider-Hohendorf T, et al. (2014) VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J Exp Med 211(9):1833-1846.
39. Zingoni A, Ardolino M, Santoni A, Cerboni C (2013) NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: Role in the NK cell-mediated negative regulation of T cell responses. Front Immunol 3(408):408.
40. Kim HS, Das A, Gross CC, Bryceson YT, Long EO (2010) Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. Immunity 32(2):175-186.
41. Kim HS, Long EO (2012) Complementary phosphorylation sites in the adaptor protein SLP-76 promote synergistic activation of natural killer cells. Sci Signal 5(232):ra49.
42. Hamann I, et al. (2013) Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation. J Neuroimmunol 254(1-2):165-169.
43. Burshtyn DN, Shin J, Stebbins C, Long EO (2000) Adhesion to target cells is disrupted by the killer cell inhibitory receptor. Curr Biol 10(13):777-780.
44. Yednock TA, et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against α 4 β 1 integrin. Nature 356(6364):63-66.
45. Flodström-Tullberg M, Bryceson YT, Shi FD, Höglund P, Ljunggren HG (2009) Natural killer cells in human autoimmunity. Curr Opin Immunol 21(6):634-640.
46. Lünemann A, Lünemann JD, Münz C (2009) Regulatory NK-cell functions in inflammation and autoimmunity. Mol Med 15(9-10):352-358.
47. Fogel LA, Yokoyama WM, French AR (2013) Natural killer cells in human autoimmune disorders. Arthritis Res Ther 15(4):216.
48. Gandhi R, Laroni A, Weiner HL (2010) Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 221(1-2):7-14.
49. de Andrade LF, Smyth MJ, Martinet L (2014) DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol 92(3):237-244.
50. Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107(1):159-166.
51. Yamashita-Kanemaru Y, et al. (2015) CD155 (PVR/Necl5) mediates a costimulatory signal in CD4+ T cells and regulates allergic inflammation. J Immunol 194(12): 5644-5653.
52. Enqvist M, et al. (2015) Coordinated expression of DNAM-1 and LFA-1 in educated NK cells. J Immunol 194(9):4518-4527.
53. Carlsten M, et al. (2009) Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 183(8):4921-4930.
54. Chan CJ, et al. (2014) The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 15(5):431-438.
55. Stanietsky N, et al. (2009) The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 106(42):17858-17863.
56. Chan A, et al. (2007) CD56bright human NK cells differentiate into CD56dim cells: Role of contact with peripheral fibroblasts. J Immunol 179(1):89-94.
57. Huntington ND, et al. (2009) IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 206(1):25-34.
58. Perry JS, et al. (2012) Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med 4(145): 145ra106.
59. Kasaian MT, et al. (2002) IL-21 limits NK cell responses and promotes antigen-specific T cell activation: A mediator of the transition from innate to adaptive immunity. Immunity 16(4):559-569.
60. Li Q, et al. (2015) Multiple effects of IL-21 on human NK cells in ex vivo expansion. Immunobiology 220(7):876-888.
61. Shi FD, Van Kaer L (2006) Reciprocal regulation between natural killer cells and autoreactive T cells. Nat Rev Immunol 6(10):751-760.
62. Gold R, et al.; SELECT study investigators (2013) Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): A randomised, double-blind, placebocontrolled trial. Lancet 381(9884):2167-2175.
63. Martínez-Rodríguez JE, et al. (2010) Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy. Clin Immunol 137(1): 41-50.
64. Wuest SC, et al. (2011) A role for interleukin-2 trans-presentation in dendritic cellmediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 17(5):604-609.
65. Dubois S, Mariner J, Waldmann TA, Tagaya Y (2002) IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17(5):537-547.
66. Anton OM, Vielkind S, Peterson ME, Tagaya Y, Long EO (2015) NK Cell Proliferation Induced by IL-15 Transpresentation Is Negatively Regulated by Inhibitory Receptors. J Immunol 195(10):4810-4821.
67. Polman CH, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292-302.
68. Brück W, et al. (1995) Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 38(5):788-796.
69. Posevitz-Fejfár A, et al. (2014) Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: Implications for immune cell biobanking. PLoS One 9(12):e115920.
70. Martinez E, Brzostowski JA, Long EO, Gross CC (2011) Cutting edge: NKG2Ddependent cytotoxicity is controlled by ligand distribution in the target cell membrane. J Immunol 186(10):5538-5542.
71. Lueg G, et al. (2015) Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiol Aging 36(1): 81-89.
72. Gross CC, Brzostowski JA, Liu D, Long EO (2010) Tethering of intercellular adhesion molecule on target cells is required for LFA-1-dependent NK cell adhesion and granule polarization. J Immunol 185(5):2918-2926.
73. Grützke B, et al. (2015) Fingolimod treatment promotes regulatory phenotype and function of B cells. Ann Clin Transl Neurol 2(2):119-130.
74. Sloan KE, et al. (2004) CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 4(73):73.